Browse the corpus

Apixaban is a novel oral anticoagulant approved by the US Food and Drug Administration (FDA) in 2012 for use in patients with nonvalvular atrial fibrillation to reduce the risk of stroke and blood clots. Later, in 2014, apixaban gained approval for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as for reducing the risk of blood clots (DVT and PE) in patients who have undergone knee or hip replacement surgery. The drug is also approved for reducing the risk of recurrent DVT and PE after initial therapy. This activity outlines the indications, mechanism of action, safe administration, adverse effects, contraindications, monitoring, overdose management, and toxicity of apixaban, thereby providing clinicians with a robust understanding of apixaban for treating various conditions and facilitating informed decision-making. This activity emphasizes that premature apixaban discontinuation heightens thrombotic event risks, necessitating consideration of alternative anticoagulants. By addressing these significant topics, this activity aims to enhance the proficiency and competence of healthcare professionals in managing apixaban therapy, thereby leading to improved patient outcomes. Objectives: Identify appropriate indications for apixaban therapy across various clinical scenarios, including nonvalvular atrial fibrillation, deep vein thrombosis, pulmonary embolism, and post-surgical prophylaxis. Implement evidence-based protocols for initiating, titrating, and monitoring apixaban therapy according to established guidelines and patient-specific factors. Assess patients regularly for bleeding risk factors, adherence to apixaban therapy, and signs of adverse effects, ensuring timely intervention and adjustment of treatment plans when necessary. Collaborate with other healthcare professionals to ensure seamless care coordination and continuity in apixaban therapy management based on patient characteristics, comorbidities, and preferences. Access free multiple choice questions on this topic.

Prothrombin complex concentrates (PCCs) are a mixture of factors II, IX, and X. Some PCCs include factor VII. Since the 1960s, it has been known to reverse laboratory measures and bleeding from factor Xa inhibitors such as rivaroxaban, apixaban, and edoxaban in healthy volunteers, animal models, and in vitro studies of healthy donor blood. One institution instituted a protocol of administering 4-factor PCC for patients with rivaroxaban-associated or apixaban-associated bleeding requiring immediate reversal. However, whether this strategy results in clinical improvements for such patients has yet to be determined.[28] Ciraparantag, an investigational therapy, demonstrates a dose-dependent reversal of anticoagulation from steady-state apixaban or rivaroxaban treatment. However, it is important to emphasize that ciraparantag is not yet FDA-approved, stressing the necessity for further research and evaluation, particularly in toxicity.[29]

All interprofessional healthcare team members, including clinicians, specialists (cardiologists, internists, hospitalists, hematologists, and others), nursing staff, and pharmacists who treat patients with atrial fibrillation should be well informed regarding pharmacotherapy with apixaban. The FDA approved this NOAC for use in patients with nonvalvular atrial fibrillation to reduce the risk of stroke and blood clots, and it was later approved to treat DVT and PE. In 2014, the drug was also FDA-approved to reduce the risk of blood clots (DVT and PE) in patients following knee and hip replacement surgery.[30] A study examined the role of pharmacists within the interprofessional healthcare team. Implementing a pharmacist-driven DOAC protocol (pre-intervention and post-intervention) reduced the percentage of inappropriately administered DOACs, including apixaban, highlighting the vital contribution of pharmacists in optimizing anticoagulant therapy and preventing potential adverse events.[31] Unlike warfarin, the drug is relatively safe and does not need INR monitoring. However, ongoing close monitoring of patients taking apixaban is necessary to prevent bleeding; to this end, all clinicians, nurses, and pharmacists should counsel the patient so they are aware of the early signs of potential bleeding that could lead to more severe events. If an overdose occurs, immediate action is necessary, including consultation with a hematologist. A critical care physician should supervise appropriate medical management in the medical intensive care unit. If any healthcare team member detects signs of bleeding, it is imperative to promptly communicate this to the prescriber to facilitate timely therapeutic intervention. Collaboratively, the interprofessional team must operate as a cohesive unit to ensure the safety and efficacy of apixaban treatment for their patients, ultimately aiming for optimal patient outcomes while minimizing adverse events.